Human immunodeficiency virus (HIV) is\u00a0treatment is typically initiated with daily administration of\u00a0costly yet highly effective antiretroviral therapies from multiple drug classes in order to achieve the clinical goal of viral suppression.\u00a0The U.S. HIV\u00a0market for anitretroviral therapies comprises many single-tablet regimens such as Gilead\u2019s Atripla, Genvoya, and Stribld and ViiV\u2019s Triumeq; fixed-dose combinations such as GIlead\u2019s Truvada and Janssen\u2019s Prezcobix; and individual therapies such as ViiV\u2019s Tivicay\u00a0that are combined into complete regimens. The recent release of TAF-containing FDCs and STRs\u00a0offering HIV patients a reduced risk for\u00a0long-term comorbidities,\u00a0such as renal toxicity and bone demineralization, have caused a shift in prescribing habits. As such, Gilead\u2019s Genvoya and Descovy and Gilead\/Janssen\u2019s Odefsey have seen substantial uptake, particularly among recently treated patients switching part or all of their treatment regimen. \u00a0Further, protease inhibitors co-formulated with pharmacokinetic\u00a0boosters such as Janssen\u2019s Prezcobix and Bristol Myers-Squibb\u2019s Evotaz are gaining substantial patient share at the expense of other therapies in the protease inhibitor drug class.\u00a0<\/p>\n
QUESTIONS ANSWERED<\/p>\n
\u00b7 What patient share do key therapies and brands garner by line of therapy in newly diagnosed HIV\u00a0patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed HIV\u00a0patients?<\/p>\n
\u00b7 How have TAF-containing FDCs and STRs\u00a0been integrated into the treatment algorithm?<\/p>\n
\u00b7 What proportion of HIV\u00a0patients receive antiretroviral drug therapy within a\u00a0year\u00a0of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within that year\u00a0of diagnosis?<\/p>\n
\u00b7 What percentage of HIV patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/p>\n
\u00b7 What are the product-level compliance and persistency rates among drug-treated HIV patients?<\/p>\n","protected":false},"template":"","class_list":["post-390915","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-human-immunodeficiency-virus","biopharma-therapy-areas-infectious-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390915\/revisions"}],"predecessor-version":[{"id":394039,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390915\/revisions\/394039"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}